AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
70_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
3_CD
Exceptional_JJ
items_NN
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Accrual_NN
related_VBN [WZPAST]
to_PIN
Zoladex_NN
investigation_NOMZ
350_CD
Integration_NOMZ
and_PHC
synergy_NN
costs_NN
202_CD
Exceptional_JJ
items_NN
included_VBN [WZPAST]
in_PIN
operating_GER
profit_NN
350_CD
202_CD
Profit_NN
on_PIN
sale_NN
of_PIN
fixed_JJ
assets_NN
10_CD
Total_JJ
exceptional_JJ
items_NN
before_IN
taxation_NOMZ
350_CD
192_CD
Net_JJ
taxation_NOMZ
credit_NN
54_CD
Total_JJ
exceptional_JJ
items_NN
after_IN
taxation_NOMZ
350_CD
138_CD
There_EX
were_VBD
no_SYNE
exceptional_JJ
items_NN
in_PIN
2003_CD
._.
As_IN
set_VBN
out_PIN
in_PIN
more_EMPH
detail_NN
in_PIN
Note_NN
31_CD
,_,
the_DT
Company_NN
announced_VBD [PUBV]
on_PIN
20_CD
June_NN
2003_CD
a_DT
settlement_NOMZ
of_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
investigation_NOMZ
into_PIN
the_DT
US_FPP1
sales_NN
and_PHC
marketing_GER
practices_NN
for_PIN
Zoladex_NN
goserelin_NN
acetate_NN
implant_VPRT
._.
Negotiations_NOMZ
towards_PIN
this_DEMO
settlement_NOMZ
were_VBD [SPAU] [PASS]
sufficiently_RB
advanced_VBN
to_TO
recognize_VB [PRIV]
an_DT
exceptional_JJ
charge_NN
of_PIN
$_$
350m_CD
at_PIN
31_CD
December_NN
2002_CD
._.
The_DT
difference_NN
between_PIN
the_DT
final_JJ
settlement_NOMZ
of_PIN
$_$
355m_CD
and_CC
the_DT
2002_CD
exceptional_JJ
charge_NN
of_PIN
$_$
350m_CD
amounting_GER
to_TO
$_$
5m_CD
has_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
to_TO
operating_VBG
profit_NN
before_IN
exceptional_JJ
items_NN
in_PIN
2003_CD
._.
The_DT
integration_NOMZ
and_PHC
synergy_NN
program_NN
initiated_VBN [WZPAST]
in_PIN
1999_CD
was_VBD [PASS]
completed_VBN
during_PIN
2001_CD
,_,
with_PIN
final_JJ
exceptional_JJ
charges_NN
of_PIN
$_$
202m_CD
,_,
principally_RB
for_PIN
manpower_NN
related_VBN
costs_NN
,_,
IT_PIT
costs_NN
and_PHC
contractors_NN
._.
4_CD
Net_JJ
interest_NN
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Interest_NN
receivable_NN
and_CC
similar_JJ
income_NN
from_PIN
investments_NOMZ
Securities_NOMZ
21_CD
21_CD
19_CD
Short_JJ
term_NN
deposits_NN
75_CD
90_CD
179_CD
Exchange_NN
gains_NN
19 61 115 117_CD
199_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
Loan_NN
interest_NN
7_CD
10_CD
32_CD
Interest_NN
on_PIN
short_JJ
term_NN
borrowings_GER
and_CC
other_JJ
financing_GER
costs_NN
16_CD
51_CD
35_CD
Discount_NN
on_PIN
liability_NOMZ
3_CD
10_CD
15_CD
Exchange_NN
losses_NN
16_CD
12_CD
26_CD
87_CD
94_CD
Net_JJ
interest_NN
receivable_NN
89_CD
30_CD
105_CD
